实现全面皮肤清除及更高目标。
Complete skin clearance and beyond.
机构信息
Department of Public Health and Clinical Medicine, Dermatology, Umeå University, Umeå, SE-901 87, Sweden.
Centre for Pharmacoepidemiology, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
出版信息
Br J Dermatol. 2021 Jan;184(1):3-4. doi: 10.1111/bjd.19544. Epub 2020 Oct 8.
Abstract
Warren 2021; :50–59.
摘要
沃伦 2021 年；50-59.
相似文献
1
Complete skin clearance and beyond.实现全面皮肤清除及更高目标。
Br J Dermatol. 2021 Jan;184(1):3-4. doi: 10.1111/bjd.19544. Epub 2020 Oct 8.
2
Brodalumab in the treatment of chronic plaque psoriasis.布罗达卢单抗治疗慢性斑块型银屑病。
Expert Opin Biol Ther. 2020 Oct;20(10):1175-1186. doi: 10.1080/14712598.2020.1776256. Epub 2020 Jun 16.
3
Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.使用托珠单抗治疗类风湿关节炎时出现银屑病。
J Rheumatol. 2012 Mar;39(3):657. doi: 10.3899/jrheum.111166.
4
Tildrakizumab for treating psoriasis.替拉珠单抗治疗银屑病。
Expert Opin Biol Ther. 2017 May;17(5):645-657. doi: 10.1080/14712598.2017.1304537. Epub 2017 Mar 17.
5
[Monoclonal antibodies in dermatological practice].[皮肤科实践中的单克隆抗体]
Pol Merkur Lekarski. 2005 Dec;19(114):839-42.
6
Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.司库奇尤单抗治疗银屑病的临床疗效与安全性
Actas Dermosifiliogr. 2017 May;108(4):305-314. doi: 10.1016/j.ad.2016.09.021. Epub 2016 Nov 22.
7
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.用于治疗银屑病的抗白细胞介素 12、-23 和 -17 的单克隆抗体。
Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498.
8
Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.司库奇尤单抗：一种用于治疗中度至重度斑块状银屑病的新型抗白细胞介素-17A单克隆抗体疗法。
Expert Opin Biol Ther. 2016;16(2):255-63. doi: 10.1517/14712598.2016.1132695. Epub 2016 Jan 25.
9
Complete remission of psoriasis following bevacizumab therapy for colon cancer.贝伐单抗治疗结肠癌后银屑病完全缓解。
Clin Exp Dermatol. 2009 Jul;34(5):e202-4. doi: 10.1111/j.1365-2230.2008.02991.x. Epub 2008 Dec 9.
10
Therapeutic implications of IL-17A blockade in psoriasis.白细胞介素-17A阻断在银屑病中的治疗意义
Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:1-5. doi: 10.1016/S0001-7310(14)70012-2.
引用本文的文献
1
Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population.有银屑病家族史患者的临床特征：一项针对中国汉族人群的观察性流行病学研究。
Front Med (Lausanne). 2024 Aug 16;11:1455953. doi: 10.3389/fmed.2024.1455953. eCollection 2024.
2
Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry.使用系统性生物疗法的银屑病患者近乎完全清除皮肤症状的持久性：来自CorEvitas银屑病登记处的真实世界证据。
Dermatol Ther (Heidelb). 2023 Nov;13(11):2753-2768. doi: 10.1007/s13555-023-01028-5. Epub 2023 Sep 27.
3
Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry.皮肤清除与银屑病患者治疗失败率降低相关：来自CorEvitas银屑病登记处的真实世界证据。
Dermatol Ther (Heidelb). 2023 Nov;13(11):2739-2751. doi: 10.1007/s13555-023-01027-6. Epub 2023 Sep 27.
本文引用的文献
1
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.司库奇尤单抗与瑞莎珠单抗治疗中度至重度斑块状银屑病患者的疗效与安全性比较（IMMerge）：一项III期随机开放标签、疗效评估者设盲临床试验的结果
Br J Dermatol. 2021 Jan;184(1):50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6.
2
Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.一项全国性瑞典研究表明，皮肤银屑病与躯体共病与精神疾病的发生有关。
JAMA Dermatol. 2020 Jul 1;156(7):795-804. doi: 10.1001/jamadermatol.2020.1398.
3
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.在中重度斑块型银屑病患者中，连续 risankizumab 治疗与停药治疗的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723.
4
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.
5
Psoriasis therapy in real life: the need for registries.现实生活中的银屑病治疗：建立登记系统的必要性。
Dermatology. 2006;213(4):327-30. doi: 10.1159/000096196.
Zotero 插件